Since April 2022 Neuro-Bio has had 4 peer-reviewed articles accepted. We are very proud that Neuro-Bio 2022 publications are all in the TOP 5% of journals as they have Impact Factor equal to or greater than 6. Click here to have more information...
Neuro-Bio’s manuscript entitled “ Characterisation of a Bioactive Peptide T14 in the Human and Rodent Substantia nigra: Implications for Neurodegenerative Disease” has been accepted for publication at the International Journal of Molecular Sciences. To read the...
Neuro-Bio’s CEO, Susan Greenfield, had a very personal and interesting interview for the Australian Financial Review. Click the link to read the full article.
Neuro-Bio’s paper has been published on “International Journal of Biochemistry and Cell Biology” with the title WHEN A TROPHIC PROCESS TURNS TOXIC: ALZHEIMER’S DISEASE AS AN ABERRANT RECAPITULATION OF A DEVELOPMENTAL MECHANISM. Garcia-Ratés, Sara;...
Susan Greenfield, Founder and CEO of Neuro-Bio Ltd, shared her insights on the challenges of developing Alzheimer’s disease treatments, and the fundamental flaw with approaches to date on the “European Biopharmaceutical Review”. To read the full article,...
During her trip to Australia, Neuro-Bio’s CEO, Susan Greenfield had an interview with Julie Hare, Education editor for the Australian “Financial Review”. In April, Baroness Professor Greenfield published a research paper that proved a drug developed...
